
|Articles|June 14, 2007
Sirion advances two products into Phase III
Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
Advertisement
Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
The programmes will evaluate ST-601 as a therapy for the treatment of anterior uveitis and ST-603 as a potential therapy for dry eye syndrome.
The addition of these two Phase III studies brings the number of Sirion's active clinical programmes to five.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Navigating MIGS and other modern glaucoma procedures
2
IGS 2026: The expanding role of artificial intelligence in ophthalmology
3
IGS 2026: Considering OCT in neuro-ophthalmology and neurological diseases
4
IGS 2026: Current clinical perspectives on optic disc drusen
5





























